Cipla, a global pharmaceutical company, today announced that it has signed an agreement with Serum Institute of India (SII), a global leader in the production of vaccines, to exclusively market flu vaccine Nasovac-S in India.

Under this agreement, SII will develop and manufacture the vaccine, and Cipla will exclusively market it in India. The vaccine will be manufactured in Serum's world class production facilities approved by the WHO.

Subhanu Saxena, MD & Global CEO, Cipla said, ''We are extremely delighted to have entered into a strategic partnership with SII in India. This collaboration is aligned with our commitment to access to affordable healthcare. This partnership is a significant step towards making preventative healthcare accessible to a large number of Indians through Cipla's strong countrywide salesforce.''

Shares of the company gained Rs 0.95, or 0.14%, to trade at Rs 660.15. The total volume of shares traded was 92,381 at the BSE (3.19 p.m., Wednesday).